Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0798 • ACR Convergence 2025
Inhibition of Wnt Signaling Attenuates Inflammatory Arthritis Severity
Alisa Mueller¹, Angela Zou², Lucy-Jayne Marsh³, Samuel Kemble³, Saba Nayar³, Gerald Watts⁴, Cassandra Murphy⁵, Emily Taylor³, Triin Major³, David Gardner⁶, Christopher Buckley⁷, Kevin Wei⁸, Soumya Raychaudhuri⁵, ilya Korsunsky⁵, Andrew Filer⁹, Adam Croft¹⁰ and Michael Brenner¹¹, ¹Stanford University and VA Palo Alto Health Care System, Stanford, CA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶University of Birmingham, Havelock North, New Zealand, ⁷University of Oxford, Oxford, United Kingdom, ⁸Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁹The University of Birmingham, Birmingham, United Kingdom, ¹⁰University of Birmingham, Hagley, Stourbridge, United Kingdom, ¹¹Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Fibroblasts are critical in promoting pathogenic synovial inflammation and bone erosion in rheumatoid arthritis (RA). Moreover, recent studies have pointed to their potential contribution…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 0479 • ACR Convergence 2025
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Shiamak Cooper³, Sanjana Thimmannagari¹ and Anthony Ocon⁴, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Irondequoit, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are immunomodulatory agents commonly used in the treatment of rheumatoid arthritis and COVID-19. Prior studies have implicated…
Abstract Number: 0464 • ACR Convergence 2025
Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Solana Cushing¹, Kelsey Gripp², Edward DiCarlo³, Deanna Jannat-Khah¹, Yoshimi Endo³, Jose Rodriguez³, Mark Figgie³, Bella Mehta⁴ and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Reoperations following arthroplasty are a significant burden to patients and surgeons. In patients with RA who receive total hip (THA) or knee (TKA) arthroplasty,…
Abstract Number: 0446 • ACR Convergence 2025
A Balancing Act: The Interplay Between Resilience and Frailty in Rheumatoid Arthritis
Hannah Brubeck¹, Kylie Riggles¹, Adrienne Tanus¹, Nadine El-ayache², George Mount², Elizabeth Wahl², Courtney Loecker³, Jose Garcia⁴, Dolores Shoback⁵, Joshua Baker⁶, Patti Katz⁷, Ariela Orkaby⁸ and Katherine Wysham⁹, ¹VA Puget Sound Health Care System, Seattle, WA, ²VA Puget Sound Health Care System & University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷UCSF, San Rafael, CA, ⁸VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ⁹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty, a state of decreased physiological reserve and heightened vulnerability to stressors, occurs prematurely in rheumatoid arthritis (RA) and is associated with poor health…
Abstract Number: 0430 • ACR Convergence 2025
Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
fatih ŞAhiner¹, Mine Nokay², funda erbasan², Veli Yazisiz³ and Ender terzioglu², ¹Akdeniz University, Antalya, ²Akdeniz University, Antalya, Turkey, ³Akdeniz University, Faculty of Medicine, Antalya, Turkey
Background/Purpose: RA-ILD is significant determinants of morbidity and mortality. This study aims to evaluate the demographic and serological characteristics of RA-ILD patients and investigate the…
Abstract Number: 0222 • ACR Convergence 2025
Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
Isaac Smith¹, Linda Tovar², Michael Battistone², Andrea Barker³, Bryant England⁴, Ankoor Shah⁵, Joshua Baker⁶, Katherine Wysham⁷, Beth Wallace⁸, Ted Mikuls⁴, Deanna Lazaro⁹, Pascale Schwab¹⁰, Paul Monach¹¹, Gail Kerr¹², Andreas Reimold¹³, Gary Kunkel², Liron Caplan¹⁴, John Richards¹⁵, Aleksander Lenert¹⁶, Andrew Jones¹⁷, Maria I. ("Maio") Danila¹⁸, Brian Sauer¹⁹, Jorge Rojas²⁰ and Grant Cannon²¹, ¹Duke University Hospital, Durham, NC, ²Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA, Cottonwood Heights, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Duke University, Durham, NC, ⁶University of Pennsylvania, Philadelphia, PA, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹VA New York Harbor Healthcare System, Brooklyn, NY, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹³Dallas VA Medical Center, Dallas, TX, ¹⁴University of Colorado, Denver, CO, ¹⁵Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁶Iowa Carver College of Medicine, Iowa City, IA, ¹⁷VA Saint Louis and Washington University, Saint Louis, ¹⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ²⁰VA Puget Sound Health Care System, Seattle, WA, ²¹University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Collection of disease activity measures (DAMs) is a key component of high-quality care for rheumatoid arthritis (RA) patients. This study surveyed rheumatology providers at…
Abstract Number: 0155 • ACR Convergence 2025
Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
Kelsey Coziahr¹, Harlan Sayles¹, Tate Johnson¹, Joshua Baker², Punyasha Roul³, Grant Cannon⁴, Gary Kunkel⁵, Bryant England¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Post-traumatic stress disorder (PTSD) is associated with increased systemic inflammation that may increase the risk of developing autoimmune disorders such as rheumatoid arthritis (RA).…
Abstract Number: 0084 • ACR Convergence 2025
Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Keita Okamoto¹, Yasuto Araki², Yoshimi Aizaki², Hiroshi Kajiyama³, Kazuhiro Yokota², Yu Funakubo², Yuho Kadono⁴, Yuji Akiyama⁵ and Toshihide Mimura⁶, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-chou, Iruma-gun, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, ⁶Saitama Seikeikai Hospital, Higashimatsuyama, Saitama, Japan
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASFs) produce various matrix metalloproteinases (MMPs), cytokines, and chemokines. Histone lysine methylation has been shown to play an important role…
Abstract Number: 0066 • ACR Convergence 2025
RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Yidan Wang¹, Samuel Dowling², Jessica Maciuch², Vanessa Manada De Lobos², Meghan Mayer², Kainat Mian¹, Tyler Therron³, Hadijat Makinde¹, Carla Marie Cuda¹, Deborah Rachelle Winter⁴ and Harris R Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University, Skokie, IL
Background/Purpose: Tissue-resident monocyte-lineage cell (TRMC) are an extravascular population distinct from circulating monocytes and synovial macrophages and are critical for the development of inflammatory arthritis.…
Abstract Number: 0013 • ACR Convergence 2025
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Xiaofeng Zhao¹, Xiaoqing Liu¹, Yuxi Yan², Tiezheng Liu³, Yong Fu³, Yulan Hu², Kangmin Zhou², Minyun Zhou⁴, Yingying Hu² and Shunwei Zhu², ¹State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing
Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
Abstract Number: 2639 • ACR Convergence 2025
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
VINOD GUPTA¹, Adam Koller¹, Benjamin Hur¹, Marissa Bailey¹, Kara Delger², Elena myasoedova¹, Vanessa Kronzer¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, ROCHESTER, MN, ²Mayo Clinic, St Charles, MN
Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…
Abstract Number: 2288 • ACR Convergence 2025
Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)
Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
Abstract Number: 2272 • ACR Convergence 2025
Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort
Francesco NATALUCCI¹, Cécile VAN MULLEM¹, Aleksandra AVRAMOVSKA¹, Tatiana SOKOLOVA² and Patrick Durez¹, ¹Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Several bDMARDs and tsDMARDs target different key players in the immune-regulatory pathways,…
Abstract Number: 2256 • ACR Convergence 2025
Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
Qurat Ul Ain¹ and MIrza faris Ali Baig², ¹Medstar Georgetown University Hospital, Arlington, VA, ²Medstar Health, Arlington, VA
Background/Purpose: The increased risk of cardiovascular morbidity and mortality with rheumatoid arthritis has been increasingly acknowledged over the past decades. Cardiovascular disease risk management for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].